Show simple item record

dc.contributor.authorAlsayed, Shahinda S.R.
dc.contributor.authorLun, S.
dc.contributor.authorPayne, Alan
dc.contributor.authorBishai, William R.
dc.contributor.authorGunosewoyo, Hendra
dc.date.accessioned2023-03-15T06:55:30Z
dc.date.available2023-03-15T06:55:30Z
dc.date.issued2021
dc.identifier.citationAlsayed, S.S.R. and Lun, S. and Payne, A. and Bishai, W.R. and Gunosewoyo, H. 2021. Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives. Chemical Biology and Drug Design. 97 (6): pp. 1137-1150.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/90990
dc.identifier.doi10.1111/cbdd.13836
dc.description.abstract

Several rationally designed isoniazid (INH), pyrazinamide (PZA) and ciprofloxacin (CPF) derivatives were conveniently synthesized and evaluated in vitro against H37Rv Mycobacterium tuberculosis (M. tb) strain. CPF derivative 16 displayed a modest activity (MIC = 16 µg/ml) and was docked into the M. tb DNA gyrase. Isoniazid-pyrazinoic acid (INH-POA) hybrid 21a showed the highest potency in our study (MIC = 2 µg/ml). It also retained its high activity against the other tested M. tb drug-sensitive strain (DS) V4207 (MIC = 4 µg/ml) and demonstrated negligible cytotoxicity against Vero cells (IC50 ≥ 64 µg/ml). Four tested drug-resistant (DR) M. tb strains were refractory to 21a, similar to INH, whilst being sensitive to CPF. Compound 21a was also inactive against two non-tuberculous mycobacterial (NTM) strains, suggesting its selective activity against M. tb. The noteworthy activity of 21a against DS strains and its low cytotoxicity highlight its potential to treat DS M. tb.

dc.languageEnglish
dc.publisherWILEY
dc.relation.sponsoredbyhttp://purl.org/au-research/grants/arc/DE160100482
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectBiochemistry & Molecular Biology
dc.subjectChemistry, Medicinal
dc.subjectPharmacology & Pharmacy
dc.subjectciprofloxacin
dc.subjecthybrid molecules
dc.subjectindoleamides
dc.subjectisoniazid
dc.subjectpyrazinamide
dc.subjecttuberculosis
dc.subjectciprofloxacin
dc.subjecthybrid molecules
dc.subjectindoleamides
dc.subjectisoniazid
dc.subjectpyrazinamide
dc.subjecttuberculosis
dc.subjectAnimals
dc.subjectAntitubercular Agents
dc.subjectBinding Sites
dc.subjectCatalytic Domain
dc.subjectCell Survival
dc.subjectChlorocebus aethiops
dc.subjectCiprofloxacin
dc.subjectDNA Gyrase
dc.subjectDrug Design
dc.subjectDrug Resistance, Bacterial
dc.subjectIsoniazid
dc.subjectMicrobial Sensitivity Tests
dc.subjectMolecular Conformation
dc.subjectMolecular Docking Simulation
dc.subjectMycobacterium tuberculosis
dc.subjectNontuberculous Mycobacteria
dc.subjectPyrazinamide
dc.subjectStructure-Activity Relationship
dc.subjectVero Cells
dc.subjectVero Cells
dc.subjectAnimals
dc.subjectMycobacterium tuberculosis
dc.subjectIsoniazid
dc.subjectPyrazinamide
dc.subjectCiprofloxacin
dc.subjectDNA Gyrase
dc.subjectAntitubercular Agents
dc.subjectMicrobial Sensitivity Tests
dc.subjectDrug Resistance, Bacterial
dc.subjectCell Survival
dc.subjectBinding Sites
dc.subjectCatalytic Domain
dc.subjectMolecular Conformation
dc.subjectStructure-Activity Relationship
dc.subjectDrug Design
dc.subjectNontuberculous Mycobacteria
dc.subjectMolecular Docking Simulation
dc.subjectChlorocebus aethiops
dc.titleFacile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives
dc.typeJournal Article
dcterms.source.volume97
dcterms.source.number6
dcterms.source.startPage1137
dcterms.source.endPage1150
dcterms.source.issn1747-0277
dcterms.source.titleChemical Biology and Drug Design
dc.date.updated2023-03-15T06:55:30Z
curtin.note

This is the peer reviewed version of the following article: Alsayed, SSR, Lun, S, Payne, A, Bishai, WR, Gunosewoyo, H. Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives. Chem Biol Drug Des. 2021; 97: 1137– 1150, which has been published in final form at https://doi.org/10.1111/cbdd.13836. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

curtin.departmentSchool of Molecular and Life Sciences (MLS)
curtin.departmentCurtin Medical School
curtin.accessStatusOpen access
curtin.facultyFaculty of Science and Engineering
curtin.facultyFaculty of Health Sciences
curtin.contributor.orcidGunosewoyo, Hendra [0000-0003-3897-1948]
curtin.contributor.orcidPayne, Alan [0000-0003-4530-6348]
curtin.contributor.researcheridPayne, Alan [G-4995-2015]
dcterms.source.eissn1747-0285
curtin.contributor.scopusauthoridGunosewoyo, Hendra [16480496000]
curtin.contributor.scopusauthoridPayne, Alan [8731082200]
curtin.repositoryagreementV3


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record